Table 2.

Red blood cell transfusion in 1,000 patients with thalassemia

Characteristics	Patients (n=1,000)
Frequency of transfusion, n (%)
1 week	1 (0.1)
2 weeks	12 (1.2)
3 weeks	122 (12.2)
4 weeks	598 (59.8)
5 weeks	23 (23.0)
6 weeks	112 (11.3)
8 weeks	127 (12.8)
Other	5 (0.5)
Volume of RBCs per transfusion, n (%)
1 unit	158 (15.8)
2 units	566 (56.6)
5–10 mL/kg	14 (1.4)
10–12 mL/kg	63 (6.3)
12–15 mL/kg	176 (17.6)
> 15 mL/kg	9 (0.9)
Other	14 (1.4)
Type of red blood cell products*, n (%)
Red Blood Cells (RBCs)	33 (3.3)
Leukocyte-poor RBCs	548 (54.8)
Leukocyte-depleted RBCs	625 (62.5)
Single-donor RBCs	2 (0.2)
Transfusion-related adverse events**, n (%)
None	643 (64.3)
Anaphylaxis	6 (0.6)
Febrile non-hemolytic transfusion reaction (FNHTR)	54 (5.4)
Alloantibody	156 (15.6)
Allergic reactions	130(13.0)
Autoimmune hemolytic anemia	70 (7.0)
Transfusion-related infection	4 (0.4)
Transfusion-related acute lung injury (TRALI)	1 (0.1)

^*some patients received multiple types of RBC products

^**some patients have multiple adverse events